STOCK TITAN

NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

NeoGenomics (NASDAQ: NEO) will present significant research on hematologic malignancies at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego, December 7-10. The company will showcase findings on CNS lymphoma, myeloid malignancies, and gene fusions in acute myeloid leukemia.

The presentation includes a poster on neuronal-glial and immune microenvironment signatures in primary CNS lymphoma, scheduled for December 9. Additionally, two abstracts were published in the Blood supplement: one comparing genetic insights into myeloid malignancies across NCCN Guidelines, WHO Classification, and ICC System, and another studying gene fusion prevalence in 2,958 AML patients using FISH and NGS testing.

The company will also feature its hematological oncology solutions, including COMPASS, AML Express, and AML MRD Flow Panel at booth #2347.

NeoGenomics (NASDAQ: NEO) presenterà ricerche significative sulle malattie ematologiche maligne durante il 2024 American Society of Hematology (ASH) Annual Meeting a San Diego, dal 7 al 10 dicembre. L'azienda mostrerà risultati sul linfoma CNS, sulle neoplasie mieloidi e sulle fusione geniche nella leucemia mieloide acuta.

La presentazione include un poster sulle firme del microambiente neuronale-gliale e immunitario nel linfoma CNS primario, previsto per il 9 dicembre. Inoltre, sono stati pubblicati due abstract nel supplemento di Blood: uno che confronta gli approfondimenti genetici sulle neoplasie mieloidi secondo le linee guida NCCN, la classificazione WHO e il sistema ICC, e l'altro che studia la prevalenza delle fusione geniche in 2.958 pazienti con AML utilizzando test FISH e NGS.

L'azienda presenterà anche le sue soluzioni di oncologia ematologica, tra cui COMPASS, AML Express e AML MRD Flow Panel presso lo stand #2347.

NeoGenomics (NASDAQ: NEO) presentará investigaciones significativas sobre malignidades hematológicas en el 2024 American Society of Hematology (ASH) Annual Meeting en San Diego, del 7 al 10 de diciembre. La empresa mostrará hallazgos sobre linfoma CNS, malignidades mieloides y fusiones genéticas en leucemia mieloide aguda.

La presentación incluye un póster sobre las firmas del microambiente neuronal-glial e inmune en linfoma CNS primario, programado para el 9 de diciembre. Además, se publicaron dos resúmenes en el suplemento de Blood: uno que compara los conocimientos genéticos sobre malignidades mieloides según las Directrices NCCN, la Clasificación de la OMS y el Sistema ICC, y otro que estudia la prevalencia de fusiones genéticas en 2,958 pacientes con AML utilizando pruebas FISH y NGS.

La empresa también presentará sus soluciones de oncología hematológica, incluyendo COMPASS, AML Express y AML MRD Flow Panel en el stand #2347.

NeoGenomics (NASDAQ: NEO)는 샌디에고에서 열리는 2024 미국 혈액학회(ASH) 연례 회의에서 혈액 종양학 연구를 발표할 예정입니다. 회의는 12월 7일부터 10일까지 진행되며, 회사는 CNS 림프종, 골수 종양 및 급성 골수성 백혈병의 유전자 융합에 관한 발견을 선보일 것입니다.

발표에는 12월 9일에 예정된 1차 CNS 림프종의 신경-아교세포 및 면역 미세환경 서명에 대한 포스터가 포함되어 있습니다. 또한, 두 개의 초록이 Blood 보충판에 발표되었습니다: 하나는 NCCN 지침, WHO 분류 및 ICC 시스템에 따른 골수 종양에 대한 유전적 통찰을 비교하고, 또 다른 하나는 2,958명의 AML 환자에서 FISH 및 NGS 검사를 사용하여 유전자 융합의 유병률을 연구한 것입니다.

회사는 또한 부스 #2347에서 COMPASS, AML Express 및 AML MRD Flow Panel을 포함한 혈액학적 종양학 솔루션을 선보일 예정입니다.

NeoGenomics (NASDAQ: NEO) présentera des recherches significatives sur les malignités hématologiques lors de la 2024 American Society of Hematology (ASH) Annual Meeting à San Diego, du 7 au 10 décembre. L'entreprise mettra en avant des résultats sur le lymphome du SNC, les malignités myéloïdes et les fusions géniques dans la leucémie myéloïde aiguë.

La présentation comprendra une affiche sur les signatures du microenvironnement neuronal-glial et immunitaire dans le lymphome primaire du SNC, prévue pour le 9 décembre. De plus, deux résumés ont été publiés dans le supplément de Blood : l'un comparant les perspectives génétiques sur les malignités myéloïdes selon les directives NCCN, la classification de l'OMS et le système ICC, et un autre étudiant la prévalence des fusions géniques chez 2 958 patients atteints de LMA utilisant des tests FISH et NGS.

L'entreprise présentera également ses solutions d'oncologie hématologique, y compris COMPASS, AML Express et AML MRD Flow Panel, au stand #2347.

NeoGenomics (NASDAQ: NEO) wird bedeutende Forschung zu hämatologischen Malignitäten auf dem 2024 American Society of Hematology (ASH) Annual Meeting in San Diego vom 7. bis 10. Dezember präsentieren. Das Unternehmen wird Ergebnisse zu CNS-Lymphomen, myeloischen Malignitäten und Genfusionen bei akuter myeloischer Leukämie vorstellen.

Die Präsentation umfasst ein Plakat zu neuronalen-glialen und immunologischen Mikroumgebungsmerkmalen im primären CNS-Lymphom, das für den 9. Dezember geplant ist. Darüber hinaus wurden zwei Abstracts im Blut-Supplement veröffentlicht: einer vergleicht genetische Einsichten in myeloische Malignitäten gemäß den NCCN-Leitlinien, der WHO-Klassifikation und dem ICC-System, und der andere untersucht die Prävalenz von Genfusionen bei 2.958 AML-Patienten mit FISH- und NGS-Tests.

Das Unternehmen wird auch seine hämatologischen Onkologielösungen, einschließlich COMPASS, AML Express und AML MRD Flow Panel, am Stand #2347 vorstellen.

Positive
  • None.
Negative
  • None.

The company will showcase new insights into CNS lymphoma, myeloid malignancies, and gene fusions in acute myeloid leukemia

FT. MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will share its latest research on hematologic malignancies and the prognostic effects of microenvironment signatures in primary central nervous system (CNS) lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting, booth #2347, in San Diego, December 7-10. The company will also feature its robust hematological oncology solutions, including COMPASS, AML Express, and AML MRD Flow Panel.

“Our research at ASH demonstrates that NeoGenomics continues to advance its leadership position in precision diagnostics for hematologic cancers,” said Warren Stone, Chief Commercial Officer of NeoGenomics. “Through our collaboration with Duke University and the innovative work of our scientific team, we are uncovering critical insights into the genetic and microenvironmental factors that influence patient outcomes. These studies can potentially refine prognostic tools, align diagnostics with clinical guidelines, and ultimately improve therapeutic decision-making—enhancing care for patients battling blood cancer.”

At the meeting, NeoGenomics will present a poster:

In addition to the poster, NeoGenomics’ two abstracts were recently published in the Blood supplement and archived on the ASH and Blood abstracts site:

  • Genetic Insights into Myeloid Malignancies: A Comparative Analysis of NCCN Guidelines, the WHO Classification, and the ICC System
    • This study offers a comprehensive analysis of genetic insights into myeloid malignancies, comparing recommendations from major clinical guidelines and classifications, including the NCCN, WHO, and ICC systems.
  • A Prevalence Study of Gene Fusions in 2,958 Acute Myeloid Leukemia Patients from the Community Using FISH and NGS Testing
    • This prevalence study evaluates gene fusion occurrences in nearly 3,000 AML patients from community settings and utilizes FISH and NGS testing to uncover critical insights for diagnostic and therapeutic decision-making.

For more information about NeoGenomics’ research and presentations at ASH 2024, visit www.neogenomics.com.

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus for physicians to help them diagnose and treat cancer. The Company's Advanced Diagnostic Division also serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.

Forward-Looking Statements

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “plan,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. This press release includes forward-looking statements. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Investor Contact

Kendra Sweeney

kendra.sweeney@neogenomics.com

Media Contact

Andrea Sampson

asampson@sampsonprgroup.com

Source: NeoGenomics, Inc.

FAQ

What research will NeoGenomics (NEO) present at ASH 2024?

NeoGenomics will present research on CNS lymphoma, myeloid malignancies, and gene fusions in acute myeloid leukemia, including a poster on neuronal-glial and immune microenvironment signatures in primary CNS lymphoma.

When and where is NeoGenomics (NEO) presenting at ASH 2024?

NeoGenomics will present at the ASH Annual Meeting in San Diego from December 7-10, 2024, with their poster presentation scheduled for December 9 at 6-8 p.m. PST at booth #2347.

What products will NeoGenomics (NEO) showcase at ASH 2024?

NeoGenomics will showcase its hematological oncology solutions, including COMPASS, AML Express, and AML MRD Flow Panel.

How many AML patients were included in NeoGenomics' (NEO) gene fusion study?

NeoGenomics' prevalence study included 2,958 Acute Myeloid Leukemia (AML) patients from community settings, using FISH and NGS testing methods.

NeoGenomics, Inc.

NASDAQ:NEO

NEO Rankings

NEO Latest News

NEO Stock Data

2.20B
126.78M
1.22%
99.81%
2.82%
Diagnostics & Research
Services-testing Laboratories
Link
United States of America
FORT MYERS